Reversal of New Oral Anticoagulants

被引：23

作者：

Battinelli, Elisabeth M. ^{[1
,2
]}

机构：

[1] Brigham & Womens Hosp, Dept Med, Div Hematol, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Boston, MA USA

来源：

CIRCULATION | 2011年 / 124卷 / 14期

关键词：

Editorials; anticoagulants; DIRECT THROMBIN INHIBITOR; TOTAL KNEE ARTHROPLASTY; DABIGATRAN ETEXILATE; VENOUS THROMBOEMBOLISM; TOTAL HIP; ATRIAL-FIBRILLATION; RANDOMIZED-TRIAL; DOUBLE-BLIND; ENOXAPARIN; RIVAROXABAN;

D O I：

10.1161/CIRCULATIONAHA.111.054510

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1508 / 1510

页数：3

共 20 条

[11] Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial [J].

Kakkar, Ajay K. ;

Brenner, Benjamin ;

Dahl, Ola E. ;

Eriksson, Bengt I. ;

Mouret, Patrick ;

Muntz, Jim ;

Soglian, Andrea G. ;

Pap, Akos F. ;

Misselwitz, Frank ;

Haas, Sylvia .

LANCET, 2008, 372 (9632) :31-39

[12] Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty [J].

Lassen, Michael R. ;

Ageno, Walter ;

Borris, Lars C. ;

Lieberman, Jay R. ;

Rosencher, Nadia ;

Bandel, Tiemo J. ;

Misselwitz, Frank ;

Turpie, Alexander G. G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (26) :2776-2786

[13] Platelet activity of high-dose factor VIIa is independent of tissue factor [J].

Monroe, DM ;

Hoffman, M ;

Oliver, JA ;

Roberts, HR .

BRITISH JOURNAL OF HAEMATOLOGY, 1997, 99 (03) :542-547

[14] Rivaroxaban: A New Oral Factor Xa Inhibitor [J].

Perzborn, Elisabeth ;

Roehrig, Susanne ;

Straub, Alexander ;

Kubitza, Dagmar ;

Mueck, Wolfgang ;

Laux, Volker .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2010, 30 (03) :376-U24

[15]

RYN JV, 2010, PATHOPHYSIOL HAEMO T, V37, pA94

[16] Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. [J].

Schulman, Sam ;

Kearon, Clive ;

Kakkar, Ajay K. ;

Mismetti, Patrick ;

Schellong, Sebastian ;

Eriksson, Henry ;

Baanstra, David ;

Schnee, Janet ;

Goldhaber, Samuel Z. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (24) :2342-2352

[17] Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate An Open-Label, Parallel-Group, Single-Centre Study [J].

Stangier, Joachim ;

Rathgen, Karin ;

Stahle, Hildegard ;

Mazur, Dago .

CLINICAL PHARMACOKINETICS, 2010, 49 (04) :259-268

[18] Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial [J].

Turpie, Alexander G. G. ;

Lassen, Michael R. ;

Davidson, Bruce L. ;

Bauer, Kenneth A. ;

Gent, Michael ;

Kwong, Louis M. ;

Cushner, Fred D. ;

Lotke, Paul A. ;

Berkowitz, Scott D. ;

Bandel, Tiemo J. ;

Benson, Alice ;

Misselwitz, Frank ;

Fisher, William D. .

LANCET, 2009, 373 (9676) :1673-1680

[19] Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity [J].

van Ryn, Joanne ;

Stangier, Joachim ;

Haertter, Sebastian ;

Liesenfeld, Karl-Heinz ;

Wienen, Wolfgang ;

Feuring, Martin ;

Clemens, Andreas .

THROMBOSIS AND HAEMOSTASIS, 2010, 103 (06) :1116-1127

[20] Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty A meta-analysis [J].

Wolowacz, Sorrel E. ;

Roskell, Neil S. ;

Plumb, Jonathan M. ;

Caprini, Joseph A. ;

Eriksson, Bengt I. .

THROMBOSIS AND HAEMOSTASIS, 2009, 101 (01) :77-85

← 1 2 →